7 completed, 4 recruiting, 2 active not recruiting, 2 unknown. 18 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 7, Recruiting 4, Active not recruiting 2, Unknown 2, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
Follow Brain Tumor: new trials by email Literature Review of Brain Tumor trials Research Report on Brain Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Different Anesthetic Drugs on Electrocorticography (ECOG). Fentanyl (IV), Ketamine (0.5 mg/kg) - Epilepsy, Brain Tumor | Phase 3 | Active not recruiting | Children's Cancer Hospital Egypt 57357 | 88 | 2025-08-18 | 2025-09-10 |
| Levetiracetam Prophylaxis in Brain Tumor Resection Pilot Levetiracetam, Placebo - Seizures, Brain Tumor | Phase 3 | Not yet recruiting | Hamilton Health Sciences Corporation | 70 | 2025-03-01 | 2024-10-23 |
| A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound - Glioblastoma Multiforme, Glioblastoma | Phase 3 | Recruiting | NaviFUS Corporation | 32 | 2024-11-08 | 2026-04-09 |
| Does Perioperative Intravenous Magnesium Affect Postoperative Quality of Recovery in Craniotomy Surgery Patients? IV magnesium sulfate, Placebo - Brain Tumor, Surgery | Phase 3 | Unknown | Thomas Jefferson University | 110 | 2024-11-01 | 2023-04-12 |
| A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma Niraparib, Temozolomide - Glioblastoma, GBM | Phase 3 | Active not recruiting | Ivy Brain Tumor Center | 450 | 2024-06-19 | 2026-07-01 |
| The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION, Placebo - Brain Tumor, Bleeding | Phase 3 | Recruiting | Stephen Lownie | 102 | 2024-04-03 | 2026-03-19 |
| Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab - Brain Tumor, Non Small Cell Lung Cancer | Phase 3 | Recruiting | InSightec | 96 | 2022-08-12 | 2026-10-13 |
| 18F-DOPA II - PET Imaging Optimization 18F-DOPA, Furosemide Injection - Congenital Hyperinsulinism, Neuroblastoma | Phase 3 | Recruiting | University of Alberta | 800 | 2021-01-20 | 2026-02-09 |
| Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients Magnesium Sulfate, Sodium Chloride - Seizures (Incl Subtypes), Brain Tumor | Phase 3 | Completed | Sara Varea | 55 | 2012-10-01 | 2018-01-17 |
| Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy sodium thiosulfate, examination - Brain Tumor, Central Nervous System Tumor | Phase 3 | Completed | Children's Oncology Group | 131 | 2008-06-23 | 2023-11-09 |
| Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor filgrastim, carboplatin, cisplatin - Brain Tumor, Central Nervous System Tumor | Phase 3 | Completed | Children's Oncology Group | 24 | 2007-01-01 | 2018-09-07 |
| Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Dendritic cell immunotherapy - Glioblastoma Multiforme, Glioblastoma | Phase 3 | Unknown | Northwest Biotherapeutics | 348 | 2006-12-01 | 2022-05-18 |
| XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema hCRF, placebo hCRF - Brain Edema, Brain Tumor | Phase 3 | Withdrawn | Celtic Pharma Development Services | 120 | 2006-01-01 | 2008-01-03 |
| An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies hCRF [XERECEPT (corticorelin acetate injection)] - Brain Edema, Brain Tumor | Phase 3 | Completed | Celtic Pharma Development Services | 112 | 2005-07-01 | 2012-08-31 |
| High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas filgrastim, carboplatin, etoposide - Brain Tumor, Central Nervous System Tumor | Phase 3 | Completed | Children's Oncology Group | 1 | 2004-10-01 | 2015-05-07 |
| XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors hCRF, placebo hCRF - Brain Edema, Brain Tumor | Phase 3 | Completed | Celtic Pharma Development Services | 200 | 2004-05-01 | 2014-08-13 |
| Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning IR Methylphenidate, Modafinil, SR Methylphenidate - Brain Tumor | Phase 3 | Terminated | M.D. Anderson Cancer Center | 34 | 2004-02-01 | 2020-09-23 |
| Serial CT Scans in Fractionated Stereotactic Radiotherapy Relocatable fixation system - Brain Tumor | Phase 3 | Completed | Maastricht Radiation Oncology | 20 | 2003-11-01 | 2009-06-30 |
Brain Neoplasms (18) · Astrocytoma (4) · Brain Edema (3) · Central Nervous System Neoplasms (3) · Edema (3) · Glioblastoma (3) · Glioma (2) · Neoplasms (2) · Neuroblastoma (2) · Seizures (2) · Carcinoma, Non-Small-Cell Lung (1) · Congenital Hyperinsulinism (1) · Epilepsy (1) · Fatigue (1) · Hemorrhage (1)
Brain Diseases (18) · Central Nervous System Diseases (18) · Neoplasms by Site (18) · Nervous System Diseases (18) · Nervous System Neoplasms (18) · Neoplasms (16) · Central Nervous System Neoplasms (15) · Neoplasms by Histologic Type (9) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Glandular and Epithelial (9) · Neoplasms, Neuroepithelial (9) · Neuroectodermal Tumors (9) · Neoplasms, Nerve Tissue (8) · Pathological Conditions, Signs and Symptoms (8) · Glioma (6)
Corticotropin-Releasing Hormone (3) · Carboplatin (2) · Etoposide (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Magnesium Sulfate (2) · Sodium Chloride (2) · etoposide phosphate (2) · 4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid (1) · Bevacizumab (1) · Cisplatin (1) · Cyclophosphamide (1) · Fentanyl (1) · Furosemide (1) · Injections, Intravenous (1)
Celtic Pharma Development Services (3) · Children's Oncology Group (3) · Children's Cancer Hospital Egypt 57357 (1) · Hamilton Health Sciences Corporation (1) · InSightec (1) · Ivy Brain Tumor Center (1) · M.D. Anderson Cancer Center (1) · Maastricht Radiation Oncology (1) · NaviFUS Corporation (1) · Northwest Biotherapeutics (1) · Sara Varea (1) · Stephen Lownie (1) · Thomas Jefferson University (1) · University of Alberta (1)
Canada (11) · United States (10) · Australia (4) · Germany (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Egypt (1) · France (1) · Italy (1) · Norway (1) · Puerto Rico (1) · South Korea (1) · Switzerland (1) · Taiwan (1)
William Shapiro, MD (3) · Brigitta Baumert, PHD (1) · David R. Freyer, DO, MS (1) · Jeffrey C. Allen, MD (1) · Jeffrey S. Wefel, PhD (1) · Jonathan Abele, MD (1) · Kevin Min, MD (1) · Linda Liau, M.D. (1) · Manmeet Ahluwalia, MD, MBA (1) · Marnix L. Bosch, MBA, PhD (1) · Nader Sanai, MD (1) · Neus Fabregas, MD PhD (1) · Sharon L. Gardner, MD (1) · Stephen Lownie, MD (1) · Suzan A. Abdelrahman, consultant (1)
PMID 20554319, PMID 22194025, PMID 23382470, PMID 23545055, PMID 24266542, PMID 25534062, PMID 25558198, PMID 27914822, PMID 28283245, PMID 29843811, PMID 31831982, PMID 34824110, PMID 34952528, PMID 36394838, PMID 38052364
U10CA098543 (1)